ArticleBlood vessels, thrombosis & hemostasis2026
NETs contribute to acute episodes but not ADAMTS13 relapses in immune-mediated thrombotic thrombocytopenic purpura.
Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) results from acquired severe deficiency of a disintegrin and metalloprotease with thrombospondin type 1 motifs, member 13 (ADAMTS13). Neutrophil extracellular traps (NETs) contribute to acute iTTP episodes, but their role across different clinical stages and treatment modalities remains unclear. We conducted a retrospective, observational study in 8 patients with iTTP followed up for 7.4 years (range, 0.4-15.2). Patients experienced 8 first acute episodes (3 caplacizumab treated), 14 ADAMTS13 relapses, and 6 clinical relapses (2 caplacizumab treated), interjected by remissions. Besides clinical and ADAMTS13 parameters, we measured NET markers, including circulating DNA, myeloperoxidase (MPO), neutrophil elastase, and citrullinated histone H3. All NET markers were elevated at presentation with acute iTTP episodes and rapidly declined during treatment. The magnitude of NET marker reduction 3 days after treatment initiation was similar with and without caplacizumab (DNA, -61% ± 21% vs -49% ± 23%; MPO, -15% ± 49% vs -46% ± 33%). In the second week, patients treated without caplacizumab presented with another NET marker surge, paralleled by a drop in platelet counts; both were absent in caplacizumab-treated patients. NET levels remained unchanged during ADAMTS13 relapses compared to remission (DNA, 1.1-fold; MPO, 1.1-fold), whereas increases were documented in overt clinical relapses (DNA, 4.3-fold; MPO, 3.2-fold). Our findings indicate NET involvement in acute iTTP pathophysiology but suggest that NET formation requires a secondary trigger beyond ADAMTS13 deficiency. The second wave of NET formation and renewed platelet decline may be driven by von Willebrand factor-platelet interactions, as the phenomenon is absent in caplacizumab-treated patients. Our data support the benefit of preemptive immunosuppressive treatment for ADAMTS13 relapses.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.